Acute toxicity after hypofractionated conformal radiotherapy for localized prostate cancer: nonrandomized contemporary comparison with standard fractionation
- PMID: 18375075
- DOI: 10.1016/j.ijrobp.2008.01.023
Acute toxicity after hypofractionated conformal radiotherapy for localized prostate cancer: nonrandomized contemporary comparison with standard fractionation
Abstract
Purpose: To prospectively study acute rectal and urinary reactions from three-dimensional conformal external beam radiotherapy for localized prostate cancer comparing two hypofractionation regimens with standard fractionation (standard). The hypofractionation regimens were designed to avoid more late reactions in the hypofractionation groups than in the standard group, with the advantage of one-half as many treatment sessions.
Patients and materials: A total of 56 nonrandomized patients chose hypofractionation delivered at 3 (n = 22) or 3.15 (n = 34) Gy/fraction, 4 d/wk, to a total dose of 60 or 63 Gy within 5 weeks. A total of 74 patients were contemporarily treated with standard fractionation at 2 Gy/fraction, 5 d/wk, to a total dose of 76 to 80 Gy.
Results: The differences within patients without complications were not statistically significant in the three groups. However, for acute complications of Grade 2 or worse, the Hypo3.15 group had significantly greater (p = 0.001) complication rates (50%) compared with the standard group (17%). The incidence of patients without acute rectal complications was significantly lower for the Hypo3.15 group compared with the Hypo3 and standard groups. The incidence of rectal Grade 2 or greater complications was correspondingly significantly greater for the Hypo3.15 group than for the Hypo3 and standard groups (p < 0.001). The incidence of patients with urinary complications was not significantly different among the three groups.
Conclusions: Acute rectal reactions were more frequent and intense in the Hypo3.15 group than in the Hypo3 and standard groups. In our study, 60 Gy at 3 Gy/fraction within 5 weeks resulted in acute toxicity similar to that after standard fractionation.
Similar articles
-
Late outcomes following hypofractionated conformal radiotherapy vs. standard fractionation for localized prostate cancer: a nonrandomized contemporary comparison.Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1441-6. doi: 10.1016/j.ijrobp.2008.10.087. Epub 2009 Apr 22. Int J Radiat Oncol Biol Phys. 2009. PMID: 19395194
-
Later outcomes and alpha/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer.Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1200-7. doi: 10.1016/j.ijrobp.2010.12.040. Epub 2011 Apr 7. Int J Radiat Oncol Biol Phys. 2012. PMID: 21477933
-
Acute toxicity of image-guided hypofractionated radiotherapy for prostate cancer: nonrandomized comparison with conventional fractionation.Urol Oncol. 2011 Sep-Oct;29(5):523-32. doi: 10.1016/j.urolonc.2009.10.004. Epub 2009 Dec 16. Urol Oncol. 2011. PMID: 20005749
-
Comparison of late rectal toxicity from conventional versus three-dimensional conformal radiotherapy for prostate cancer: analysis of clinical and dosimetric factors.Urology. 2005 Jan;65(1):114-9. doi: 10.1016/j.urology.2004.08.037. Urology. 2005. PMID: 15667875 Review.
-
Hypofractionated radiotherapy for prostate cancer.Radiat Oncol. 2014 Dec 6;9:275. doi: 10.1186/s13014-014-0275-6. Radiat Oncol. 2014. PMID: 25480014 Free PMC article. Review.
Cited by
-
Hypofractionated radiotherapy for localised prostate cancer. Review of clinical trials.Clin Transl Oncol. 2009 Jul;11(7):437-45. doi: 10.1007/s12094-009-0382-2. Clin Transl Oncol. 2009. PMID: 19574201 Review.
-
Does radiotherapy increase the risk of colorectal cancer among prostate cancer patients? A large population-based study.J Cancer. 2020 Aug 25;11(21):6204-6212. doi: 10.7150/jca.44726. eCollection 2020. J Cancer. 2020. PMID: 33033503 Free PMC article.
-
Prognostic factors for acute toxicity in prostate cancer patients treated with high-dose hypofractionated radiotherapy.Clin Transl Oncol. 2013 Aug;15(8):643-51. doi: 10.1007/s12094-012-0987-8. Epub 2013 Jan 29. Clin Transl Oncol. 2013. PMID: 23359176
-
Phase II Trial of Pure Hypofractionated Radiotherapy in the Treatment of Localized Carcinoma of the Prostate.Cureus. 2018 Oct 9;10(10):e3435. doi: 10.7759/cureus.3435. Cureus. 2018. PMID: 30546982 Free PMC article.
-
The case for hypofractionation of localized prostate cancer.Rev Urol. 2013;15(3):113-7. Rev Urol. 2013. PMID: 24223023 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical